Advertisement
Advertisement
U.S. Markets open in 8 hrs 32 mins
Advertisement
Advertisement
Advertisement
Advertisement

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.70+0.01 (+0.15%)
At close: 04:00PM EST
6.70 0.00 (0.00%)
After hours: 07:02PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.69
Open6.57
Bid6.70 x 900
Ask6.99 x 1000
Day's Range6.48 - 6.80
52 Week Range3.48 - 13.10
Volume147,077
Avg. Volume233,817
Market Cap186.198M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-2.04
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.71
  • GlobeNewswire

    aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

    Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the United States Adopted Names (USAN) Council and the World Health Organization’s (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary nam

  • GlobeNewswire

    aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis

    Company expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, ATYR1923, for the treatment of sarcoi

  • GlobeNewswire

    aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

    SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 10 – 13, 2022. The presentation will be available on-demand to registered conference attendees starting Monday,

Advertisement
Advertisement